Europe
DBV Technologies, located just outside Paris, announced it is cutting jobs while it awaits news from the U.S. Food and Drug Administration (FDA) about its application for Viaskin Peanut.
Despite the bleak challenges brought on by COVID-19, Bill Sibold, executive vice president of Sanofi Genzyme, is optimistic that some of the greatest discoveries in medicine and treating various diseases are within the grasp of the pharmaceutical industry.
Novartis, Novartis Hellas and Alcon Inc. have agreed to pay a total of more than $346 million to settle bribery charges under the Foreign Corrupt Practices Act (FCPA), which is a U.S. anti-bribery law.
According to a brief report by Reuters, the drug company plans to hold meetings with staff representatives tomorrow and Monday of next week to describe a restructuring plan, according to four sources familiar with the matter.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 26, 2020.
The companies will work to discover, develop and commercialize novel therapies that modulate G protein-coupled receptor (GPCR) targets that AbbVie selects.
Enterome SA, based in Paris and Cambridge, Massachusetts, announced a new financing totaling $52.6 million (€46.3 million). This was a Series E round.
Biopharma and life sciences companies provide updates on their pipelines and business plans.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 24, 2020.
Relugolix is a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist.
PRESS RELEASES